Heron Therapeutics
HRTX
64 hedge funds and large institutions have $245M invested in Heron Therapeutics in 2014 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 25 increasing their positions, 9 reducing their positions, and 8 closing their positions.
9,470% more call options, than puts
Call options by funds: $957K | Put options by funds: $10K
178% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 9
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
22% more capital invested
Capital invested by funds: $202M → $245M (+$43.8M)
8% more funds holding
Funds holding: 59 → 64 (+5)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.16M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$1.97M |
| 3 |
KCM
Kingdon Capital Management
New York
|
+$1.41M |
| 4 |
RA
Royce & Associates
New York
|
+$1.39M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$809K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.12M |
| 2 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$2.42M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$2.41M |
| 4 |
PA
Perceptive Advisors
New York
|
-$1.79M |
| 5 |
FM
Forward Management
San Francisco,
California
|
-$1.42M |
HRTX Hedge Fund Activity: Q4 2014 in Review
64 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q4 2014, worth a combined $245M — up 22% from $202M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new HRTX positions and 8 closed out — a net gain of 6 holders — while 25 added to existing stakes and 9 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $4.16M. The largest seller was Federated Hermes, exiting entirely with an estimated $3.12M sold.
- 64 institutional investors held Heron Therapeutics (HRTX) as of Q4 2014, up from 59 in Q3 2014.
- Funds reported $245M of Heron Therapeutics stock for Q4 2014, up 22% quarter-over-quarter.
- 14 funds opened new Heron Therapeutics positions in Q4 2014 and 8 closed out, a net change of +6 holders.
- The largest Heron Therapeutics buyer in Q4 2014 was Point72 Asset Management, an estimated $4.16M added.
- The largest Heron Therapeutics seller in Q4 2014 was Federated Hermes, an estimated $3.12M sold.
Based on aggregated 13F filings for Q4 2014.